阿替利珠单抗联合奥妥珠单抗和苯达莫司汀治疗初治滤泡性淋巴瘤的安全性与疗效
这项Ib/II期 trial 在40例初治滤泡性淋巴瘤患者中评估阿替利珠单抗联合奥妥珠单抗和苯达莫司汀的安全性与疗效。独立评审委员会评估的完全缓解率为75.0%(95%CI 61.3%至85.8%),3年研究者评估的无进展生存率和总生存率分别为80.9%和89.3%。5例患者报告5级(致死性)不良事件,该方案疗效似乎不优于GALLIUM试验中的奥妥珠单抗联合苯达莫司汀,且因安全性不佳不能推荐用于初治滤泡性淋巴瘤患者。
要点
- 独立评审委员会评估的完全缓解率为75.0%(95%CI 61.3%至85.8%)。
- 3年研究者评估的无进展生存率为80.9%(95%CI 63.9%至90.5%),总生存率为89.3%(95%CI 73.9%至95.9%)。
- 5例患者报告5级(致死性)不良事件,因安全性不佳该方案不能推荐用于初治滤泡性淋巴瘤。
核心结论
- 阿替利珠单抗联合奥妥珠单抗和苯达莫司汀在初治滤泡性淋巴瘤中的疗效似乎不优于GALLIUM试验中奥妥珠单抗联合苯达莫司汀的疗效。
- 在奥妥珠单抗联合苯达莫司汀基础上加用阿替利珠单抗与不良事件风险增加相关。
- 特别由于不利的安全性特征,该方案不能推荐用于初治滤泡性淋巴瘤患者。
研究设计与样本
- Ib/II期 trial(#NCT02596971),先进行安全性导入期,随后进入扩展期。
- 扩展期采用阿替利珠单抗联合奥妥珠单抗和苯达莫司汀诱导,随后阿替利珠单抗联合奥妥珠单抗维持治疗≤24个月。
- 共入组并治疗40例初治滤泡性淋巴瘤患者。
- 主要终点为独立评审委员会(IRC)按改良Lugano 2014标准评估的完全缓解率。
主要发现
- 独立评审委员会评估的完全缓解率为75.0%(95%CI 61.3%至85.8%)。
- 3年研究者评估的无进展生存率为80.9%(95%CI 63.9%至90.5%),总生存率为89.3%(95%CI 73.9%至95.9%)。
- 基线时21/40例患者有循环淋巴瘤特异性克隆型,诱导结束时重复检测均达到微小残留病阴性(10^-5灵敏度),其中16例(76.2%)为完全缓解、3例(14.3%)为部分缓解、2例(9.5%)为疾病稳定(IRC评估)。
- 5例患者报告5级(致死性)不良事件。
临床怎么用
- 作者结论指出,特别由于不利的安全性特征,该方案不能推荐用于初治滤泡性淋巴瘤患者。
局限性
- 原文结论指出该方案疗效似乎不优于GALLIUM试验中奥妥珠单抗联合苯达莫司汀的疗效,且加用阿替利珠单抗与不良事件风险增加相关。
- 原文结论指出特别由于不利的安全性特征,该方案不能推荐用于初治滤泡性淋巴瘤患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obinutuzumab (G) chemoimmunotherapy demonstrated improved progression-free survival (PFS) vs rituximab-based chemoimmunotherapy in patients with previously untreated follicular lymphoma (FL) in the GALLIUM trial. Atezolizumab (atezo) is a programmed death-ligand 1 inhibitor with a complementary mechanism of action to G by restoring cytotoxic T-cell function. We evaluated the safety and efficacy of atezo-G-bendamustine in patients with previously untreated FL in a phase Ib/II trial (#NCT02596971). A safety run-in phase was followed by an expansion phase with atezo-G-bendamustine induction and atezo-G maintenance for ≤24 months. Forty patients with previously untreated FL were enrolled and treated with atezo-G-bendamustine. The primary endpoint, complete response (CR) rate, assessed by an independent review committee (IRC; modified Lugano 2014 criteria) was 75.0% (95% confidence interval [CI], 61.3% to 85.8%). Three-year investigator-assessed PFS and overall survival rates were 80.9% (95% CI, 63.9% to 90.5%) and 89.3% (95% CI, 73.9% to 95.9%), respectively. At baseline, 21/40 patients had circulating lymphoma-specific clonotypes and underwent repeat testing at end of induction; all were minimal residual disease negative (10-5 sensitivity), with 16 (76.2%) CRs, 3 (14.3%) partial responses, and 2 (9.5%) with stable disease (IRC assessed). Grade 5 (fatal) adverse events (AEs) were reported in 5 patients. The efficacy of atezo-G-bendamustine in previously untreated FL did not appear superior to G-bendamustine efficacy as seen in the GALLIUM trial, and the addition of atezo to G-bendamustine was associated with an increased risk of AEs. Particularly due to the unfavorable safety profile, this regimen cannot be recommended in patients with previously untreated FL. This trial was registered at www.clinicaltrials.gov as #NCT02596971.
引用
- Younes A, Burke JM, Diefenbach C, et al. Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma. Blood Adv. 2022. PMID: 35359000. doi:10.1182/bloodadvances.2021006131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。